Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Guy

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Acta Radiologica (Stockholm, Sweden : 1987)|January 22, 2010
Revascularization of traumatic renal artery dissection by endoluminal stenting: three casesPascal Chabrot, Lucie Cassagnes, Agaïcha Alfidja, et al.
Journal of Surgical Oncology|October 30, 2015
Previous radiation for prostate neoplasm alters surgical and oncologic outcomes after rectal cancer surgeryMarlène Guandalino, Aurélien Dupré, Marie François, et al.
In Vivo (Athens, Greece)|October 25, 2011
miRNAs differentially expressed in prostate cancer cell lines after soy treatmentNadège Rabiau, Hibatullahi-Kauthar Trraf, Mawussi Adjakly, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 27, 2014
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter studyChristian Pfister, Walid Kerkeni, Jerome Rigaud, et al.
Future Oncology (London, England)|February 5, 2021
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysisMathieu Roumiguié, Xavier Paoletti, Yann Neuzillet, et al.
Urology|January 31, 2006
Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancerAurélie Cabrespine, Laurent Guy, Elhani Khenifar, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Oncology Reports|June 14, 2011
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detectionNadège Rabiau, Pierre Déchelotte, Mawussi Adjakly, et al.
Nutrition and Cancer|March 20, 2014
Comparative effects of soy phytoestrogens and 17β-estradiol on DNA methylation of a panel of 24 genes in prostate cancer cell linesMawussi Adjakly, Marjolaine Ngollo, André Lebert, et al.
Endocrinology|May 2, 2012
Lxrα regulates the androgen response in prostate epitheliumEmilie Viennois, Teresa Esposito, Julie Dufour, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Acta Radiologica (Stockholm, Sweden : 1987)|January 22, 2010
Revascularization of traumatic renal artery dissection by endoluminal stenting: three casesPascal Chabrot, Lucie Cassagnes, Agaïcha Alfidja, et al.
Journal of Surgical Oncology|October 30, 2015
Previous radiation for prostate neoplasm alters surgical and oncologic outcomes after rectal cancer surgeryMarlène Guandalino, Aurélien Dupré, Marie François, et al.
In Vivo (Athens, Greece)|October 25, 2011
miRNAs differentially expressed in prostate cancer cell lines after soy treatmentNadège Rabiau, Hibatullahi-Kauthar Trraf, Mawussi Adjakly, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 27, 2014
Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter studyChristian Pfister, Walid Kerkeni, Jerome Rigaud, et al.
Future Oncology (London, England)|February 5, 2021
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysisMathieu Roumiguié, Xavier Paoletti, Yann Neuzillet, et al.
Urology|January 31, 2006
Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancerAurélie Cabrespine, Laurent Guy, Elhani Khenifar, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Oncology Reports|June 14, 2011
BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detectionNadège Rabiau, Pierre Déchelotte, Mawussi Adjakly, et al.
Nutrition and Cancer|March 20, 2014
Comparative effects of soy phytoestrogens and 17β-estradiol on DNA methylation of a panel of 24 genes in prostate cancer cell linesMawussi Adjakly, Marjolaine Ngollo, André Lebert, et al.
Endocrinology|May 2, 2012
Lxrα regulates the androgen response in prostate epitheliumEmilie Viennois, Teresa Esposito, Julie Dufour, et al.
Pageof 9